Controlled absorption diltiazem pharmaceutical formulation

Details Controlled absorption diltiazem pharmaceutical formulation Controlled absorption diltiazem pharmaceutical formulation

1999-04-07

2000-03-07

Harrison, Robert H.

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Particulate form

424457, 424458, 424459, 424461, 424462, 424490, 424494, A61K 954

Patent

active

060336870

ABSTRACT:
A controlled absorption diltiazem pellet formulation for oral administration comprises a core having diltiazem or a pharmaceutically acceptable salt thereof as the active ingredient. The core is surrounded by a coating which has only a single layer which is comprised of a relatively major proportion of talc and relatively minor proportion of sodium lauryl sulfate admixed with a minor proportion of a pharmaceutically acceptable film-forming, first polymer permeable to water and diltiazem, and a major proportion of a pharmaceutically acceptable film-forming, second polymer that is less permeable to water and diltiazem than the first polymer. The core and the coating layer both exclude organic acids. The composition of the coating layer as well as the proportion of core to coating layer are effective to permit release of the diltiazem allowing controlled absorption following oral administration. By combining short lag and long lag pellets into a single formulation, the release of diltiazem is controlled over a twenty four hour period.

REFERENCES:
patent: 3607364 (1971-09-01), Lopez et al.
patent: 3835221 (1974-09-01), Fulberth et al.
patent: 4496558 (1985-01-01), DeMarinis et al.
patent: 4610870 (1986-09-01), Jain et al.
patent: 4721619 (1988-01-01), Panoz et al.
patent: 4828840 (1989-05-01), Sakamoto et al.
patent: 4891230 (1990-01-01), Geoghegan et al.
patent: 4894240 (1990-01-01), Geoghegan et al.
patent: 4904476 (1990-02-01), Mehta et al.
patent: 4917899 (1990-04-01), Geoghegan et al.
patent: 4960596 (1990-10-01), Debregeas et al.
patent: 5000962 (1991-03-01), Sangekar et al.
patent: 5002276 (1991-03-01), Geoghegan et al.
patent: 5133974 (1992-07-01), Paradissis et al.
patent: 5137733 (1992-08-01), Noda et al.
patent: 5149542 (1992-09-01), Valducci
patent: 5202128 (1993-04-01), Morella et al.
patent: 5219621 (1993-06-01), Geoghegan et al.
patent: 5229131 (1993-07-01), Amidon et al.
patent: 5229135 (1993-07-01), Philippon et al.
patent: 5252337 (1993-10-01), Powell
patent: 5254347 (1993-10-01), Samejima et al.
patent: 5286497 (1994-02-01), Hendrickson et al.
patent: 5336504 (1994-08-01), Geoghegan et al.
patent: 5344657 (1994-09-01), Desmolin
patent: 5364620 (1994-11-01), Geoghegan et al.
patent: 5376384 (1994-12-01), Eichel et al.
patent: 5439689 (1995-08-01), Hendrickson et al.
patent: 5470584 (1995-11-01), Hendrickson et al.
patent: 5529790 (1996-06-01), Eichel et al.
patent: 5567441 (1996-10-01), Chen
patent: 5616345 (1997-04-01), Geoghegan et al.
patent: 5622716 (1997-04-01), Barth
patent: 5670172 (1997-09-01), Buxton et al.
patent: 5834024 (1998-11-01), Heinicke et al.
patent: 5879714 (1999-03-01), Sherman
patent: 5922352 (1999-07-01), Chen et al.
patent: 5958458 (1999-09-01), Norling et al.
patent: 5968552 (1999-10-01), Sherman

Affiliated with

Also associated with

Rating

Controlled absorption diltiazem pharmaceutical formulation does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Controlled absorption diltiazem pharmaceutical formulation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Controlled absorption diltiazem pharmaceutical formulation will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-360380